Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases
Pharmacology Research & Perspectives · 2026-06 · 14 (3)
DOI: 10.1002/prp2.70261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 22.05.2026. Verfasst von María Larrosa-García und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Service, Vall D'hebron Hospital Campus, Barcelona, Spain. Hauptthemen laut MEDLINE: Receptors, IgG, Rituximab, Immunologic Factors. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Societat Catalana de Farmacai Clínica.
Abstract (Originalsprache)
Rituximab is an anti‐CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on rituximab efficacy in glomerular diseases. A clinical trial was performed including adults with glomerular diseases who required rituximab (NEFRTX; EudraCT: 2020–000484‐23). Patients received 1.0 g or 0.5 g of rituximab on day 1 (± day 14); biochemical parameters and rituximab concentration were measured, and FCGR2A and FCGR3A variants were characterized. Clinical outcome was evaluated at 6 and 12 months. 30 patients were included. FCGR2A (rs1801274) and FCGR3A (rs396991) variants did not show an effect on clinical response to rituximab. When the effect of the variant was corrected by rituximab exposure, the expression of the FCGR2A rs1801274‐A allele vs. no expression was related to a poorer response at month 6 (odds ratio 0.034; 95% confidence interval 0.002–0.725; p = 0.030); this effect was not seen for FCGR3A . Additional studies involving larger cohorts are warranted to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacy Service, Vall D'hebron Hospital Campus, Barcelona, Spain.
- Vall D'hebron Institute of Research, Barcelona, Spain.
- Clinical Nephrology Service, Vall D'hebron Hospital Campus, Barcelona, Spain.
- Pharmacogenetics Unit. Hospital Universitario Virgen de Las Nieves, Granada, Spain.
- Clinical Pharmacy Service, Hospital Universitario Virgen de Las Nieves, Granada, Spain.
- Immunology Division, Vall D'hebron Barcelona Hospital Campus, Barcelona, Spain.
ORCID-Profile: María Larrosa-García, Susana Rojo Tolosa
Förderung
- Societat Catalana de Farmacai Clínica
Zitieren
APA
Larrosa-García, M., Pamplona, I. A., Tolosa, S. R., Morales, A. J., Martínez, M. T. S., Gallo, M. M., Colobran, R., Vicente, H. G., Pena, N. M., Macías, R. P. B., & Ronsano, J. B. M. (2026). Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases. Pharmacology Research & Perspectives, 14(3). https://doi.org/10.1002/prp2.70261
Vancouver
Larrosa-García M, Pamplona IA, Tolosa SR, Morales AJ, Martínez MTS, Gallo MM, et al. Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases. Pharmacology Research & Perspectives. 2026;14(3). doi:10.1002/prp2.70261
BibTeX
@article{LarrosaGarca2026,
author = {Larrosa-García, María and Pamplona, Irene Agraz and Tolosa, Susana Rojo and Morales, Alberto Jiménez and Martínez, María Teresa Sanz and Gallo, Mónica Martínez and Colobran, Roger and Vicente, Helena Genestal and Pena, Nerea Moreno and Macías, Roxana Paola Bury and Ronsano, José Bruno Montoro},
title = {Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {3},
doi = {10.1002/prp2.70261}
}
EUVIMED